Prelude Therapeutics (NASDAQ: PRLD) has appointed Dr. Charles Morris as chief medical officer (CMO), effective April 20, 2026.
Dr. Morris is a medical oncologist with more than 30 years of oncology drug development experience working with global biotech and pharmaceutical companies and managing multiple drug approvals. Most recently, he served as CMO at Lava Therapeutics.
In a statement, Kris Vaddi, CEO of Prelude, commented, “We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as executive vice president and CMO. With our two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer advancing expected to enter into clinical development in 2026, Dr. Morris’s deep clinical experience, track record of developing successful oncology medicines and proven leadership will be instrumental in ensuring we execute these programs with both rigor and strategic insight.”
